NASDAQ:BIIB

Biogen - BIIB Stock Forecast, Price & News

$283.63

-3.89 (-1.35%)

(As of 02/3/2023 09:03 PM ET)

Add

Compare

Today's Range: $282.52
▼
$291.10
50-Day Range: $270.81
▼
$305.17
52-Week Range: $187.16
▼
$311.88

Volume: 789,100 shs
Average Volume: 1.16 million shs
Market Capitalization: $40.84 billion

P/E Ratio: 14.44
Dividend Yield: N/A
Price Target: $309.14

Institutional Ownership

Biogen MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.71 Rating Score
Upside/Downside: 10.2% Upside
$312.56 Price Target
Short Interest: Healthy
1.32% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.85
Upright™ Environmental Score
News Sentiment: 0.64
Based on 6 Articles This Week
Insider Trading: Selling Shares
$1.68 M Sold Last Quarter
Proj. Earnings Growth: -7.78%
From $17.10 to $15.77 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.49 out of 5 stars

Medical Sector

136th out of 1,025 stocks

Biological Products, Except Diagnostic Industry

26th out of 168 stocks

3.4

Analyst's Opinion

Consensus Rating
Biogen has received a consensus rating of Buy. The company's average rating score is 2.73, and is based on 19 buy ratings, 7 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $312.56, Biogen has a forecasted upside of 10.2% from its current price of $283.63.
Amount of Analyst Coverage
Biogen has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0

Short Interest

Percentage of Shares Shorted
1.32% of the float of Biogen has been sold short.
Short Interest Ratio / Days to Cover
Biogen has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Biogen has recently increased by 10.53%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Biogen does not currently pay a dividend.
Dividend Growth
Biogen does not have a long track record of dividend growth.

4.2

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Biogen has received a 60.54% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Dimethyl fumarate ", "Natalizumab", "Neuromuscular disorders medication", and "Rituximab" products. See details.
Environmental Sustainability
The Environmental Impact score for Biogen is -1.85.

2.6

News and Social Media Coverage

News Sentiment
Biogen has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for Biogen this week, compared to 13 articles on an average week.
Search Interest
20 people have searched for BIIB on MarketBeat in the last 30 days. This is an increase of 18% compared to the previous 30 days.
MarketBeat Follows
Only 17 people have added Biogen to their MarketBeat watchlist in the last 30 days. This is a decrease of -11% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Biogen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,683,617.00 in company stock.
Percentage Held by Insiders
Only 0.65% of the stock of Biogen is held by insiders.
Percentage Held by Institutions
84.40% of the stock of Biogen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Biogen are expected to decrease by -7.78% in the coming year, from $17.10 to $15.77 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Biogen is 14.44, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 145.06.
Price to Earnings Ratio vs. Sector
The P/E ratio of Biogen is 14.44, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 150.32.
Price to Earnings Growth Ratio
Biogen has a PEG Ratio of 1.80. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Biogen has a P/B Ratio of 3.80. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Biogen (NASDAQ:BIIB) Stock

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Receive BIIB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biogen and its competitors with MarketBeat's FREE daily newsletter.

BIIB Stock News Headlines

January 30, 2023 | marketbeat.com

Cassava Sciences Stock Undervalued with Its $124 Price Target? (BIIB)

Casava Sciences Inc (NASDAQ: SAVA) stock has been the topic of much controversy in its quest for FDA approval for its simufilam drug. The Company is a

February 6, 2023 | seekingalpha.com

Biogen: What To Do Ahead Of Q4 2022 Financial Report

February 6, 2023 | Investor Place Media (Ad)

Cash Holders STILL Aren't Taking Steps to Prepare

Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.

February 1, 2023 | stocknews.com

3 Biotech Stocks to Get in on Before It’s Too Late

February 1, 2023 | americanbankingnews.com

Biogen Inc. (NASDAQ:BIIB) Receives $309.14 Average Target Price from Analysts

January 31, 2023 | americanbankingnews.com

Biogen Inc. (NASDAQ:BIIB) Short Interest Up 10.5% in January

January 30, 2023 | finance.yahoo.com

UPDATE 1-Japan gives priority review status to Alzheimer's drug developed by Eisai, Biogen

January 29, 2023 | finance.yahoo.com

LECANEMAB RECEIVES PRIORITY REVIEW STATUS IN JAPAN

February 6, 2023 | Investor Place Media (Ad)

Cash Holders STILL Aren't Taking Steps to Prepare

January 28, 2023 | americanbankingnews.com

Analysts Offer Predictions for Biogen Inc.'s FY2027 Earnings (NASDAQ:BIIB)

January 27, 2023 | americanbankingnews.com

Needham & Company LLC Comments on Biogen Inc.'s FY2022 Earnings (NASDAQ:BIIB)

January 27, 2023 | americanbankingnews.com

Biogen Inc. (NASDAQ:BIIB) Forecasted to Earn Q4 2022 Earnings of $3.56 Per Share

January 26, 2023 | finance.yahoo.com

Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease Accepted by European Medicines Agency

January 26, 2023 | finance.yahoo.com

UPDATE 1-EU regulator accepts for review Alzheimer's treatment from Eisai-Biogen

January 26, 2023 | markets.businessinsider.com

Where Biogen Stands With Analysts

January 26, 2023 | marketwatch.com

Biogen Inc. stock outperforms market despite losses on the day

January 26, 2023 | marketwatch.com

Biogen Inc. stock outperforms market on strong trading day

January 26, 2023 | finance.yahoo.com

The Petri Dish: Morphic, J&J part ways; FDA committee to review another Biogen drug

January 24, 2023 | finance.yahoo.com

Biogen Inc. (BIIB) Stock Moves -0.02%: What You Should Know

January 24, 2023 | finance.yahoo.com

Why Biogen Inc. (BIIB) Could Beat Earnings Estimates Again

January 24, 2023 | stocknews.com

1 High-Yield Dividend Stock You Can Count on in 2023

January 20, 2023 | finance.yahoo.com

Why the FDA didn’t grant an approval to Lilly’s Alzheimer’s drug

January 20, 2023 | finance.yahoo.com

The FDA Rejected Lilly’s Alzheimer’s Drug. Why It’s Only a Setback,

January 20, 2023 | finance.yahoo.com

In A Stunner, Eli Lilly Stock Falls After FDA Delivers A Blow To Its Alzheimer's Drug

January 20, 2023 | finance.yahoo.com

Eli Lilly Stock Slips Lower As FDA Rejects Fast Track Approval For Alzheimer's Drug

January 19, 2023 | ca.finance.yahoo.com

Eli Lilly says U.S. FDA rejects accelerated approval for Alzheimer's drug

January 19, 2023 | finance.yahoo.com

If You Invested $25,000 in Biogen in 2018, This Is How Much You Would Have Today

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive BIIB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biogen and its competitors with MarketBeat's FREE daily newsletter.

BIIB Company Calendar

Last Earnings: 10/19/2021
Today: 2/06/2023
Next Earnings (Confirmed): 2/15/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:BIIB
CUSIP: 09062X10
CIK: 875045
Web: www.biogen.com
Phone: (617) 679-2000
Fax: 617-679-2617
Employees: 9,610
Year Founded: 1978

Price Target and Rating

Average Stock Price Forecast: $312.56
High Stock Price Forecast: $370.00
Low Stock Price Forecast: $225.00
Forecasted Upside/Downside: +9.0%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.71
Research Coverage: 26 Analysts

Profitability

EPS (Most Recent Fiscal Year): $19.64
Trailing P/E Ratio: 14.44
Forward P/E Ratio: 16.59
P/E Growth: 1.8
Net Income: $1.56 billion
Net Margins: 27.64%
Pretax Margin: 32.74%
Return on Equity: 21.31%
Return on Assets: 10.24%

Debt

Debt-to-Equity Ratio: 0.49
Current Ratio: 2.49
Quick Ratio: 2.14

Sales & Book Value

Annual Sales: $10.98 billion
Price / Sales: 3.72
Cash Flow: $27.17 per share
Price / Cash Flow: 10.44
Book Value: $74.61 per share
Price / Book: 3.80

Miscellaneous

Outstanding Shares: 144,000,000
Free Float: 143,065,000
Market Cap: $40.84 billion
Optionable: Optionable
Beta: 0.22

Social Links

Key Executives

Christopher A. Viehbacher
President, Chief Executive Officer & Director

Alphonse Galdes
EVP-Pharmaceutical Operations & Technology

Michael R. McDonnell
Chief Financial Officer & Executive Vice President

Mahalakshmi Radhakrishnan
Chief Medical Officer & Group Senior VP

Priya Singhal
Executive VP, Head-Research & Development

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

BIIB Stock - Frequently Asked Questions

Should I buy or sell Biogen stock right now?: 26 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last twelve months. There are currently 7 hold ratings and 19 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BIIB shares.
View BIIB analyst ratings or view top-rated stocks.
What is Biogen's stock price forecast for 2023?: 26 analysts have issued twelve-month price objectives for Biogen's stock. Their BIIB share price forecasts range from $225.00 to $370.00. On average, they anticipate the company's share price to reach $312.56 in the next year. This suggests a possible upside of 10.2% from the stock's current price.
View analysts price targets for BIIB or view top-rated stocks among Wall Street analysts.
How have BIIB shares performed in 2023?: Biogen's stock was trading at $276.92 on January 1st, 2023. Since then, BIIB shares have increased by 2.4% and is now trading at $283.63.
View the best growth stocks for 2023 here.
Are investors shorting Biogen?: Biogen saw a increase in short interest in January. As of January 15th, there was short interest totaling 1,890,000 shares, an increase of 10.5% from the December 31st total of 1,710,000 shares. Based on an average daily trading volume, of 1,300,000 shares, the days-to-cover ratio is presently 1.5 days. Approximately 1.3% of the shares of the stock are short sold.
View Biogen's Short Interest.
When is Biogen's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 15th 2023.
View our BIIB earnings forecast.
How can I listen to Biogen's earnings call?: Biogen will be holding an earnings conference call on Wednesday, February 15th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.
How were Biogen's earnings last quarter?: Biogen Inc. (NASDAQ:BIIB) posted its earnings results on Tuesday, October, 19th. The biotechnology company reported $4.77 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $4.09 by $0.68. The biotechnology company had revenue of $2.78 billion for the quarter, compared to analysts' expectations of $2.67 billion. Biogen had a trailing twelve-month return on equity of 21.31% and a net margin of 27.64%. Biogen's revenue for the quarter was down 17.7% on a year-over-year basis. During the same quarter last year, the business posted $8.84 earnings per share.
Read the conference call transcript.
What is Michel Vounatsos' approval rating as Biogen's CEO?: 394 employees have rated Biogen Chief Executive Officer Michel Vounatsos on Glassdoor.com. Michel Vounatsos has an approval rating of 86% among the company's employees. 72.0% of employees surveyed would recommend working at Biogen to a friend.

What other stocks do shareholders of Biogen own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Biogen investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Amgen (AMGN), Walt Disney (DIS), Intel (INTC), Micron Technology (MU) and Boeing (BA).
What is Biogen's stock symbol?: Biogen trades on the NASDAQ under the ticker symbol "BIIB."
Who are Biogen's major shareholders?: Biogen's stock is owned by many different retail and institutional investors. Top institutional investors include Assenagon Asset Management S.A. (0.37%), Sumitomo Mitsui Trust Holdings Inc. (0.36%), Parnassus Investments LLC (0.21%), New York State Common Retirement Fund (0.11%), New York State Teachers Retirement System (0.11%) and DekaBank Deutsche Girozentrale (0.10%). Insiders that own company stock include Alfred Sandrock, Brian S Posner, Ginger Gregory, Michel Vounatsos, Stephen A Sherwin and Susan H Alexander.
View institutional ownership trends.
How do I buy shares of Biogen?: Shares of BIIB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Biogen's stock price today?: One share of BIIB stock can currently be purchased for approximately $283.63.
How much money does Biogen make?: Biogen (NASDAQ:BIIB) has a market capitalization of $40.84 billion and generates $10.98 billion in revenue each year. The biotechnology company earns $1.56 billion in net income (profit) each year or $19.64 on an earnings per share basis.
How many employees does Biogen have?: The company employs 9,610 workers across the globe.
Does Biogen have any subsidiaries?: The following companies are subsidiares of Biogen: BIIB Colombia S.A.S., Biogen (Argentina) SRL, Biogen (Bermuda) Technologies Ltd., Biogen (Czech Republic) s.r.o., Biogen (Denmark) A/S, Biogen (RTP) Realty LLC, Biogen Australia PTY Ltd, Biogen Austria GmbH, Biogen B.V., Biogen Belgium N.V./S.A., Biogen Biotechnology (Shanghai) Co. Ltd, Biogen Brasil Produtos Farmaceuticos LTDA, Biogen Canada Inc., Biogen Chesapeake LLC, Biogen Chile Spa, Biogen Digital Health Inc., Biogen Estonia OU, Biogen Finland OY, Biogen Foundation Inc., Biogen France S.A.S., Biogen GmbH, Biogen Holding I LLC, Biogen Holding II LLC, Biogen Hong Kong Limited, Biogen Hungary KFT, Biogen Idec (Ireland) Ltd., Biogen Idec Biotech India Pvt. Ltd., Biogen Idec Limited, Biogen Idec Research Ltd., Biogen Idec Uruguay SA, Biogen International GmbH, Biogen International Holding Limited, Biogen International Neuroscience GmbH, Biogen Italia S.R.L., Biogen Japan Ltd., Biogen Korea LLC, Biogen Latvia SIA, Biogen Lithuania UAB, Biogen Luxembourg Holding S.a.r.l., Biogen MA Inc., Biogen Management Services GmbH, Biogen Manufacturing Holding LLC, Biogen Mexico S. DE R.L. DE C.V., Biogen NZ Biopharma Ltd., Biogen Netherlands B.V., Biogen New Ventures Inc., Biogen Norway AS, Biogen Pharma d.o.o., Biogen Pharma farmacevtska in biotehnoloska druzba d.o.o., Biogen Poland Sp. z.o.o., Biogen Portugal Sociedade Farmaceutica Unipessoal Lda., Biogen Realty Corporation, Biogen Realty Limited Partnership, Biogen SRO Inc., Biogen Slovakia s.r.o., Biogen Spain S.L., Biogen Sweden AB, Biogen Swiss Investments GmbH, Biogen Swiss Manufacturing GmbH, Biogen Switzerland AG, Biogen Switzerland Holdings GmbH, Biogen Taiwan Limited, Biogen Therapeutics Inc., Biogen Turkey Ilac Ticaret Limited Sirketi, Biogen U.S. Corporation, Biogen U.S. Limited Partnership, Biogen U.S. Pacific LLC, Biogen U.S. West Corporation, Conforma Therapeutics, Conforma Therapeutics Corporation, Convergence Pharmaceuticals, Convergence Pharmaceuticals Holdings Ltd., Convergence Pharmaceuticals Limited, Eidetica Biopharma GmbH, Fumapharm, IDEC Pharmaceuticals Corporation, NightstaRx Limited, Nightstar Europa Limited, Nightstar Inc., Nightstar Therapeutics Limited, Nightstar Therapeutics plc, Old Convergence Pharmaceuticals Limited, Panima Pharmaceuticals AG, Silver Acquisition Co. Ltd., Stromedix Inc., Stromedix Inc., Syntonix Pharmaceuticals Inc., TYSABRI, and Tungsten Bidco Limited.
Read More
How can I contact Biogen?: Biogen's mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The official website for the company is www.biogen.com. The biotechnology company can be reached via phone at (617) 679-2000, via email at ir@biogen.com, or via fax at 617-679-2617.

This page (NASDAQ:BIIB) was last updated on 2/6/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Biogen - BIIB Stock Forecast, Price & News

Biogen MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Biogen (NASDAQ:BIIB) Stock

BIIB Stock News Headlines

BIIB Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

BIIB Stock - Frequently Asked Questions

Overall MarketRank^™